Shui F. Wang - Publications

Profiling the Onco-metabolic Nexus and Improving Cancer Risk Prediction Performance: A Large-scale Cohort and Genome-Wide Pleiotropic Analysis.

Journal: Cancer research communications

Published: February 09, 2026

Cryoablation-guided breast-conserving surgery: a single-center, retrospective study based on a propensity score-matched cohort.

Journal: Gland surgery

Published: January 16, 2026

Correction: Comprehensive analysis of the PLXNA3 gene on prognosis and immune characteristics in breast cancer.

Journal: Scientific reports

Published: January 07, 2026

tRF-1432 orchestrates RBMS1-IMPDH2 regulatory control to drive purine-dependent chemoresistance in breast cancer.

Journal: Cancer letters

Published: December 06, 2025

AK5 suppresses breast cancer progression and modulates anti-PD-L1 efficacy via the miR-182-5p/PD-L1 axis.

Journal: iScience

Published: September 30, 2025

Predicting the sonication energy for focused ultrasound surgery treatment of breast fibroadenomas using machine learning algorithms.

Journal: International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group

Published: July 10, 2025

Exploration of precise classification and therapeutic targets of breast cancer based on genes related to neuro-cancer crosstalk.

Journal: Translational oncology

Published: June 24, 2025

De-escalated neoadjuvant nab-paclitaxel combined with pyrotinib and trastuzumab in intrinsic HER2-enriched breast cancer (NJMU-BC01): a multicenter, single-arm, phase 2 trial.

Journal: EClinicalMedicine

Published: April 29, 2025

Integrated transcriptome study reveals a stress response state CD4 +T cells related to immune tolerance in breast cancer.

Journal: Breast cancer research : BCR

Published: April 19, 2025

Tumor microenvironment delineates differential responders to trastuzumab emtansine in HER2-positive metastatic breast cancer patients previously treated with pyrotinib: an exploratory biomarker analysis of a phase II study (NJMU-BC02).

Journal: Signal transduction and targeted therapy

Published: April 07, 2025

Immunosuppressive microenvironment of liver restrains chemotherapeutic efficacy in triple-negative breast cancer.

Journal: Journal for immunotherapy of cancer

Published: February 19, 2025

N7-Methylguanine-Related Gene Signature Highlights EIF4E as a Novel Therapeutic Target in HER2-Negative Breast Cancer.

Journal: Journal of cellular and molecular medicine

Published: February 09, 2025